🎉 M&A multiples are live!
Check it out!

Livzon Pharmaceutical Gr Valuation Multiples

Discover revenue and EBITDA valuation multiples for Livzon Pharmaceutical Gr and similar public comparables like Galapagos, Pharming, and Benevolent AI.

Livzon Pharmaceutical Gr Overview

About Livzon Pharmaceutical Gr

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in PRC which is pharmaceutical manufacturing.


Founded

1992

HQ

China
Employees

8.9K+

Website

livzon.com.cn

Financials

LTM Revenue $1.6B

LTM EBITDA $457M

EV

$3.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Livzon Pharmaceutical Gr Financials

Livzon Pharmaceutical Gr has a last 12-month revenue of $1.6B and a last 12-month EBITDA of $457M.

In the most recent fiscal year, Livzon Pharmaceutical Gr achieved revenue of $1.6B and an EBITDA of $478M.

Livzon Pharmaceutical Gr expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Livzon Pharmaceutical Gr valuation multiples based on analyst estimates

Livzon Pharmaceutical Gr P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.7B $1.6B XXX XXX XXX
Gross Profit $1.1B $1.1B XXX XXX XXX
Gross Margin 66% 67% XXX XXX XXX
EBITDA $458M $478M XXX XXX XXX
EBITDA Margin 27% 29% XXX XXX XXX
Net Profit $263M $269M XXX XXX XXX
Net Margin 15% 17% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Livzon Pharmaceutical Gr Stock Performance

As of April 15, 2025, Livzon Pharmaceutical Gr's stock price is CNY 31 (or $4).

Livzon Pharmaceutical Gr has current market cap of CNY 28.4B (or $3.9B), and EV of CNY 21.5B (or $3.0B).

See Livzon Pharmaceutical Gr trading valuation data

Livzon Pharmaceutical Gr Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.0B $3.9B XXX XXX XXX XXX $0.32

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Livzon Pharmaceutical Gr Valuation Multiples

As of April 15, 2025, Livzon Pharmaceutical Gr has market cap of $3.9B and EV of $3.0B.

Livzon Pharmaceutical Gr's trades at 1.8x LTM EV/Revenue multiple, and 6.5x LTM EBITDA.

Analysts estimate Livzon Pharmaceutical Gr's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Livzon Pharmaceutical Gr and 10K+ public comps

Livzon Pharmaceutical Gr Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.0B XXX XXX XXX
EV/Revenue 1.8x XXX XXX XXX
EV/EBITDA 6.2x XXX XXX XXX
P/E 13.8x XXX XXX XXX
P/E/Growth 1.6x XXX XXX XXX
EV/FCF 8.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Livzon Pharmaceutical Gr Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Livzon Pharmaceutical Gr Valuation Multiples

Livzon Pharmaceutical Gr's NTM/LTM revenue growth is 4%

Livzon Pharmaceutical Gr's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Livzon Pharmaceutical Gr's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Livzon Pharmaceutical Gr's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Livzon Pharmaceutical Gr and other 10K+ public comps

Livzon Pharmaceutical Gr Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -5% XXX XXX XXX XXX
EBITDA Margin 29% XXX XXX XXX XXX
EBITDA Growth 4% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 33% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 24% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 9% XXX XXX XXX XXX
Opex to Revenue 41% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Livzon Pharmaceutical Gr Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Livzon Pharmaceutical Gr M&A and Investment Activity

Livzon Pharmaceutical Gr acquired  XXX companies to date.

Last acquisition by Livzon Pharmaceutical Gr was  XXXXXXXX, XXXXX XXXXX XXXXXX . Livzon Pharmaceutical Gr acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Livzon Pharmaceutical Gr

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Livzon Pharmaceutical Gr

When was Livzon Pharmaceutical Gr founded? Livzon Pharmaceutical Gr was founded in 1992.
Where is Livzon Pharmaceutical Gr headquartered? Livzon Pharmaceutical Gr is headquartered in China.
How many employees does Livzon Pharmaceutical Gr have? As of today, Livzon Pharmaceutical Gr has 8.9K+ employees.
Is Livzon Pharmaceutical Gr publicy listed? Yes, Livzon Pharmaceutical Gr is a public company listed on SHE.
What is the stock symbol of Livzon Pharmaceutical Gr? Livzon Pharmaceutical Gr trades under 000513 ticker.
When did Livzon Pharmaceutical Gr go public? Livzon Pharmaceutical Gr went public in 1993.
Who are competitors of Livzon Pharmaceutical Gr? Similar companies to Livzon Pharmaceutical Gr include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Livzon Pharmaceutical Gr? Livzon Pharmaceutical Gr's current market cap is $3.9B
What is the current revenue of Livzon Pharmaceutical Gr? Livzon Pharmaceutical Gr's last 12-month revenue is $1.6B.
What is the current EBITDA of Livzon Pharmaceutical Gr? Livzon Pharmaceutical Gr's last 12-month EBITDA is $457M.
What is the current EV/Revenue multiple of Livzon Pharmaceutical Gr? Current revenue multiple of Livzon Pharmaceutical Gr is 1.8x.
What is the current EV/EBITDA multiple of Livzon Pharmaceutical Gr? Current EBITDA multiple of Livzon Pharmaceutical Gr is 6.5x.
What is the current revenue growth of Livzon Pharmaceutical Gr? Livzon Pharmaceutical Gr revenue growth between 2023 and 2024 was -5%.
Is Livzon Pharmaceutical Gr profitable? Yes, Livzon Pharmaceutical Gr is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.